Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 9/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570967 | 0.91 | PRF1 (0.57) | PRF1PARP10PARP11MAPK1 | |
| SCHEMBL15571425 | 0.88 | PRF1 (0.60) | PRF1 | |
| SCHEMBL15570287 | 0.81 | PRF1 (0.56) | PRF1 | |
| SCHEMBL15570786 | 0.77 | PRF1 (0.58) | PRF1 | |
| SCHEMBL15571060 | 0.76 | PARP11 (0.57) | PRF1PARP10PARP11 | |
| SCHEMBL12495946 | 0.76 | MAPK1 (0.56) | PRF1PARP10PARP11MAPK1 | |
| SCHEMBL15570437 | 0.74 | PRF1 (0.62) | PRF1 | |
| SCHEMBL2020380 | 0.74 | PRF1 (0.67) | PRF1PARP10PARP11 | |
| SCHEMBL28140768 | 0.74 | PARP11 (0.74) | PARP10PARP11MAPK1 | |
| SCHEMBL15570444 | 0.74 | PRF1 (0.56) | PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| EP-2888251-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014028968-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, BAK1 | PRF1 1/4885PARP10 2783/4885PARP11 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.